Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Miyagawa, Katsutoshi ^a   Kondo, Tatsuya ^a   Goto, Rieko ^a   Matsuyama, Rina ^a   Ono, Kaoru ^a   Kitano, Sayaka ^a   Kawasaki, Shuji ^a   Igata, Motoyuki ^a   Kawashima, Junji ^a   Matsumura, Takeshi ^a   Motoshima, Hiroyuki ^a   Araki, Eiichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

ARB; DPP 4 inhibitor; Hepatic steatosis; Inflammation; Insulin resistance

Indexed keywords

ADIPONECTIN; CYTOKINE; GLUCOSE; INSULIN; TRANSCRIPTION FACTOR PDX 1; VALSARTAN; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; INSULIN RELEASE; INSULIN SENSITIVITY; MONOTHERAPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SIGNAL TRANSDUCTION;

ADAMANTANE; ADIPONECTIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FATTY LIVER; HOMEODOMAIN PROTEINS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; NITRILES; PHLORHIZIN; PYRROLIDINES; TETRAZOLES; TRANS-ACTIVATORS; VALINE;

EID: 84886735895     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-160     Document Type: Article

References (42)

1. Bergman M. Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 2013, 43(3):504-513. 10.1007/s12020-012-9830-9, 23132321.
2. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46(1):3-19.
3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820. 10.1038/414813a, 11742414.
4. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29(1):46-52. 10.1007/BF02427280, 3514343.
5. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36(8):741-744. 10.1007/BF00401145, 8405741.
6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368(9548):1696-1705. 10.1016/S0140-6736(06)69705-5, 17098089.
7. Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007, 56(12):3006-3013. 10.2337/db07-0697, 17717280.
8. Duttaroy A, Voelker F, Merriam K, Zhang X, Ren X, Subramanian K, Hughes TE, Burkey BF. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol 2011, 650(2-3):703-707.
9. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52(3):741-750. 10.2337/diabetes.52.3.741, 12606516.
10. Omar BA, Vikman J, Winzell MS, Voss U, Ekblad E, Foley JE, Ahren B. Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia 2013, 56(8):1752-1760. 10.1007/s00125-013-2927-8, 23636640.
11. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010, 24(2):79-83. 10.1016/j.jdiacomp.2009.01.004, 19261490.
12. He YL, Wang Y, Bullock JM, Deacon CF, Holst JJ, Dunning BE, Ligueros-Saylan M, Foley JE. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007, 47(5):633-641. 10.1177/0091270006299137, 17442688.
13. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012, 11:92. 10.1186/1475-2840-11-92, 3471040, 22867630.
14. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012, 35(10):2076-2082. 10.2337/dc12-0199, 3447848, 22688551.
15. Leung PS. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in type 2 diabetes. Diabet Med 2007, 24(2):110-116. 10.1111/j.1464-5491.2007.02072.x, 17257271.
16. Aguilar D, Solomon SD. ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme. Drugs 2006, 66(9):1169-1177. 10.2165/00003495-200666090-00001, 16827595.
17. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, et al. The valsartan antihypertensive long-term use evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006, 48(3):385-391. 10.1161/01.HYP.0000236119.96301.f2, 16864741.
18. van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, Diamant M. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care 2011, 34(4):845-851. 10.2337/dc10-2224, 3064038, 21330640.
19. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362(16):1477-1490.
20. Chu KY, Lau T, Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006, 55(2):367-374. 10.2337/diabetes.55.02.06.db05-1022, 16443769.
21. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005, 315(2):688-695. 10.1124/jpet.105.087064, 16027230.
22. Cheng Q, Law PK, de Gasparo M, Leung PS. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther 2008, 327(3):683-691. 10.1124/jpet.108.142703, 18787107.
23. Morino S, Kondo T, Sasaki K, Adachi H, Suico MA, Sekimoto E, Matsuda T, Shuto T, Araki E, Kai H. Mild electrical stimulation with heat shock ameliorates insulin resistance via enhanced insulin signaling. PLoS One 2008, 3(12):e4068. 10.1371/journal.pone.0004068, 2603588, 19114996.
24. Kondo T, Sasaki K, Matsuyama R, Morino-Koga S, Adachi H, Suico MA, Kawashima J, Motoshima H, Furukawa N, Kai H, et al. Hyperthermia with mild electrical stimulation protects pancreatic beta-cells from cell stresses and apoptosis. Diabetes 2012, 61(4):838-847. 10.2337/db11-1098, 3314363, 22362176.
25. Chung J, Nguyen AK, Henstridge DC, Holmes AG, Chan MH, Mesa JL, Lancaster GI, Southgate RJ, Bruce CR, Duffy SJ, et al. HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci U S A 2008, 105(5):1739-1744. 10.1073/pnas.0705799105, 2234214, 18223156.
26. Adachi H, Kondo T, Ogawa R, Sasaki K, Morino-Koga S, Sakakida M, Kawashima J, Motoshima H, Furukawa N, Tsuruzoe K, et al. An acylic polyisoprenoid derivative, geranylgeranylacetone protects against visceral adiposity and insulin resistance in high fat fed mice. Am J Physiol Endocrinol Metab 2010, 299(5):E764-E771. 10.1152/ajpendo.00075.2010, 20716696.
27. Xu F, Gao Z, Zhang J, Rivera CA, Yin J, Weng J, Ye J. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: a role of lipid mobilization and inflammation. Endocrinology 2010, 151(6):2504-2514. 10.1210/en.2009-1013, 2875813, 20339025.
28. Goossens GH. The renin-angiotensin system in the pathophysiology of type 2 diabetes. Obes Facts 2012, 5(4):611-624. 10.1159/000342776, 22986649.
29. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009, 302(2):128-139. 10.1016/j.mce.2008.12.011, 19150387.
30. Shen M, Sun D, Li W, Liu B, Wang S, Zhang Z, Cao F. The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice. Exp Diabetes Res 2012, 2012:146194. 3310178, 22474415.
31. Wu T, Dong Z, Geng J, Sun Y, Liu G, Kang W, Zhang Y, Ge Z. Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats. Eur J Pharm Sci 2011, 42(5):496-502. 10.1016/j.ejps.2011.02.005, 21345370.
32. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, Garg R. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003, 88(9):4496-4501. 10.1210/jc.2002-021836, 12970329.
33. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010, 51(5):1584-1592. 10.1002/hep.23569, 2862093, 20225248.
34. Shimizu S, Hosooka T, Matsuda T, Asahara SI, Koyanagi-Kimura M, Kanno A, Bartolome A, Etoh H, Fuchita M, Teruyama K, et al. DPP4 inhibitor vildagliptin preserves beta cell mass through amelioration of ER stress in C/EBPB transgenic mice. J Mol Endocrinol 2012, 49(2):125-135. 10.1530/JME-12-0039, 22822047.
35. Akarte AS, Srinivasan BP, Gandhi S, Sole S. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats. Eur J Pharm Sci 2012, 47(2):456-463. 10.1016/j.ejps.2012.07.003, 22800967.
36. Akarte AS, Srinivasan BP, Gandhi S. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates beta-Cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. J Diabetes Complications 2012, 26(4):266-274. 10.1016/j.jdiacomp.2012.03.013, 22626875.
37. Sato K, Nakamura A, Shirakawa J, Muraoka T, Togashi Y, Shinoda K, Orime K, Kubota N, Kadowaki T, Terauchi Y. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and beta-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet. Endocrinology 2012, 153(3):1093-1102. 10.1210/en.2011-1712, 22315446.
38. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, Nunemaker CS. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010, 55(3):715-721. 10.1161/HYPERTENSIONAHA.109.148049, 2836256, 20100990.
39. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura K, Shimamoto K. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004, 22(10):1977-1982. 10.1097/00004872-200410000-00021, 15361770.
40. Goossens GH, Moors CC, van der Zijl NJ, Venteclef N, Alili R, Jocken JW, Essers Y, Cleutjens JP, Clement K, Diamant M, et al. Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial. PLoS One 2012, 7(6):e39930. 10.1371/journal.pone.0039930, 3386933, 22768174.
41. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, Eckardt K, Kaufman JM, Ryden M, Muller S, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011, 60(7):1917-1925. 10.2337/db10-1707, 3121429, 21593202.
42. Yin M, Sillje HH, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 2011, 10:85. 10.1186/1475-2840-10-85, 3198901, 21955567.